Early Returns Law and Politics with Jan Baran: A Supreme Path: From Latin to Campaign Finance Law, to 38 Oral Arguments – Kannon Shanmugam
A Supreme Path: From Latin to Campaign Finance Law, to 38 Oral Arguments – Kannon Shanmugam
Opening Statements: The Prohibition Against Argument
Consumer Finance Monitor Podcast Episode: SCOTUS Hears Oral Argument in Cases Challenging Biden Administration Student Loan Forgiveness Plan: Observations and Predictions
Jury Charges and Oral Argument | David Keltner | Texas Appellate Law Podcast
Reflections on Sackett - Reflections on Water Podcast
#WorkforceWednesday: EEOC COVID-19 Charges Surge, NYC’s Pay Transparency Law, SCOTUS Considers PAGA - Employment Law This Week®
What will SCOTUS Decide on the OSHA ETS and CMS Vaccine and Testing Mandates?
Why Lawyers Should Care About Typography | Matthew Butterick | Texas Appellate Law Podcast
Extending into Other Media | Texas Appellate Law Podcast
A Judicial Perspective on Using Technology at Oral Argument | Judge John Owens | Texas Appellate Law Podcast
College Sports, Video Games & the Right of Publicity With Guest Michael McCann of Sportico
Game On: College Sports, Video Games & the Right of Publicity With Guest Michael McCann of Sportico
Helping the Court Decide Your Case | Justice April Farris | Texas Appellate Law Podcast
A Break Down of the SCOTUS Oral Argument on First Amendment Right to Privacy in Association
JONES DAY TALKS®: U.S. Supreme Court Hears Arguments in NCAA Antitrust Case
JONES DAY TALKS®: Women in IP: 2020 in Review and a Look Toward 2021
SCOTUS Watch: The ACA and Key Health Law Areas Justice Barrett Could Impact - Diagnosing Health Care Podcast
Personal Jurisdiction Part 3 – Oral Arguments in the Ford Cases [More with McGlinchey Ep. 12]
Practice Makes Perfect: Mock Oral Arguments and Effective Oral Advocacy
The Federal Circuit heard oral argument in Auribundo's appeal of the district court's decision in favor of plaintiff Merck, in a case captioned In re Sugammadex (alternatively, Aurobindo v. Merck Sharp and Dohme). The issue...more
On December 9, 2020, the Federal Circuit heard oral arguments on the validity of Amgen’s patents (U.S. Patent Nos. 8,829,165 and 8,859,741) on cholesterol-lowering drug Repatha. Specifically, the question came down to whether...more